resTORbio, Inc. Announces Closing Public Offering of Common Stock
BofA Merrill Lynch,
The shares were offered by resTORbio pursuant to a shelf registration statement that was previously filed with, and subsequently declared effective by, the
- BofA Merrill Lynch, Attention: Prospectus Department, NC1-004-03-43,
200 North College Street, 3rd floor, Charlotte NC28255-0001 (email: firstname.lastname@example.org); or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA02110, by telephone at (800) 808-7525, ext. 6132, or by emailing email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
resTORbio, Inc. is a clinical stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases. resTORbio’s lead program selectively inhibits TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiovascular and central nervous systems.
This press release contains "forward-looking statements" of resTORbio within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause resTORbio’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in resTORbio’s most recent annual report on Form 10-K filed on